Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 1/01/16 → 1/11/18 |
Funding
- NHMRC - National Health and Medical Research Council (Australia): A$482,589.80
Research output
- 9 Article
-
PCPro: a clinically accessible, circulating lipid biomarker signature for poor-prognosis metastatic prostate cancer
Scheinberg, T., Lin, H.-M., Fitzpatrick, M., Azad, A. A., Bonnitcha, P., Davies, A., Heller, G., Huynh, K., Mak, B., Mahon, K., Sullivan, D., Meikle, P. J. & Horvath, L. G., 5 May 2023, In: Prostate Cancer and Prostatic Diseases. 27, 1, p. 136–143 8 p.Research output: Contribution to journal › Article › Research › peer-review
Open Access11 Link opens in a new tab Citations (Scopus) -
Avelumab Combined with Stereotactic Ablative Body Radiotherapy in Metastatic Castration-resistant Prostate Cancer: The Phase 2 ICE-PAC Clinical Trial
Kwan, E. M., Spain, L., Anton, A., Gan, C. L., Garrett, L., Chang, D., Liow, E., Bennett, C., Zheng, T., Yu, J., Dai, C., Du, P., Jia, S., Fettke, H., Abou-Seif, C., Kothari, G., Shaw, M., Parente, P., Pezaro, C. & Tran, B. & 2 others, , Mar 2022, In: European Urology. 81, 3, p. 253-262 10 p.Research output: Contribution to journal › Article › Research › peer-review
65 Link opens in a new tab Citations (Scopus) -
Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer
Mak, B., Lin, H.-M., Kwan, E. M., Fettke, H., Tran, B., Davis, I. D., Mahon, K., Stockler, M. R., Briscoe, K., Marx, G., Zhang, A., Crumbaker, M., Tan, W., Huynh, K., Meikle, T. G., Mellett, N. A., Hoy, A. J., Du, P., Yu, J. & Jia, S. & 7 others, , Dec 2022, In: BMC Medicine. 20, 1, 14 p., 112.Research output: Contribution to journal › Article › Research › peer-review
Open Access19 Link opens in a new tab Citations (Scopus)